Market Research Life Sciences Market Research Pharmaceuticals Market Research Clinical Trial Market Research

Non Alcoholic Fatty Liver Disease (NAFLD) Clinical Trial Analysis by Trial Phase, Trial Status, Trial Counts, End Points, Status, Sponsor Type, and Top Countries, 2022 Update

Best Price Guarantee Length Publisher Published Date SKU
from $2,500 564 Pages GlobalData December, 2022 GBDT17685895
Best Price Guarantee
Price from $2,500
Length 564 Pages
Publisher GlobalData
Published Date December, 2022
SKU GBDT17685895

Non Alcoholic Fatty Liver Disease (NAFLD) Clinical Trial Analysis by Trial Phase, Trial Status, Trial Counts, End Points, Status, Sponsor Type, and Top Countries, 2022 Update

Summary

GlobalData's clinical trial report, “Non Alcoholic Fatty Liver Disease (NAFLD) Clinical Trial Analysis by Trial Phase, Trial Status, Trial Counts, End Points, Status, Sponsor Type, and Top Countries, 2022 Update provides an overview of Non Alcoholic Fatty Liver Disease (NAFLD) Clinical trials scenario. This report provides top line data relating to the clinical trials on Non Alcoholic Fatty Liver Disease (NAFLD). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma - Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note:Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months
Note:Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to Buy
  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level
Note:Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


  • Report Guidance
  • GlobalData Clinical Trials Report Coverage
  • Clinical Trials by Region
    • Table Figure 1: Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics, Global, Clinical Trials by Region (%), 2022*
    • Table Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics, Global, Clinical Trials by Region, 2022*
    • Clinical Trials and Average Enrollment by Country
      • Table Figure 2: Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2022*
      • Table Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2022*
      • Table Figure 3: Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2022*
      • Table Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2022*
      • Top Five Countries Contributing to Clinical Trials in Asia-Pacific
        • Table Figure 4: Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2022*
        • Table Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2022*
      • Top Five Countries Contributing to Clinical Trials in Europe
        • Table Figure 5: Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2022*
        • Table Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics Clinical Trials, Europe, Top Five Countries, 2022*
      • Top Countries Contributing to Clinical Trials in North America
        • Table Figure 6: Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics Clinical Trials, North America, Top Countries (%), 2022*
        • Table Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics Clinical Trials, North America, Top Countries, 2022*
      • Top Five Countries Contributing to Clinical Trials in Middle East and Africa
        • Table Figure 7: Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2022*
        • Table Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2022*
      • Top Countries Contributing to Clinical Trials in Central and South America
        • Table Figure 8: Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics Clinical Trials, Central and South America, Top Countries (%), 2022*
        • Table Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics Clinical Trials, Central and South America, Top Countries, 2022*
  • Clinical Trials by G7 Countries: Proportion of Non Alcoholic Fatty Liver Disease (NAFLD) to Gastrointestinal Clinical Trials
    • Table Figure 9: Proportion of Non Alcoholic Fatty Liver Disease (NAFLD) to Gastrointestinal Clinical Trials, G7 Countries (%), 2022*
    • Table Proportion of Non Alcoholic Fatty Liver Disease (NAFLD) to Gastrointestinal Clinical Trials, G7 Countries (%), 2022*
  • Clinical Trials by Phase in G7 Countries
    • Table Figure 10: Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics, G7 Countries, Clinical Trials by Phase, 2022*
    • Table Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics, G7 Countries, Clinical Trials by Phase, 2022*
  • Clinical Trials in G7 Countries by Trial Status
    • Table Figure 11: Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2022*
    • Table Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2022*
  • Clinical Trials by E7 Countries: Proportion of Non Alcoholic Fatty Liver Disease (NAFLD) to Gastrointestinal Clinical Trials
    • Table Figure 12: Proportion of Non Alcoholic Fatty Liver Disease (NAFLD) to Gastrointestinal Clinical Trials, E7 Countries (%), 2022*
    • Table Proportion of Non Alcoholic Fatty Liver Disease (NAFLD) to Gastrointestinal Clinical Trials, E7 Countries (%), 2022*
  • Clinical Trials by Phase in E7 Countries
    • Table Figure 13: Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics, E7 Countries, Clinical Trials by Phase, 2022*
    • Table Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics, E7 Countries, Clinical Trials by Phase, 2022*
  • Clinical Trials in E7 Countries by Trial Status
    • Table Figure 14: Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2022*
    • Table Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2022*
  • Clinical Trials by Phase
    • Table Figure 15: Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics, Global, Clinical Trials by Phase (%), 2022*
    • Table Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics, Global, Clinical Trials by Phase, 2022*
    • In Progress Trials by Phase
      • Table Figure 16: Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics, Global, Clinical Trials In Progress by Phase, 2022*
      • Table Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics, Global, Clinical Trials In Progress by Phase 2022*
  • Clinical Trials by Trial Status
    • Table Figure 17: Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics, Global, Clinical Trials by Trial Status, 2022*
    • Table Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics, Global, Clinical Trials by Trial Status, 2022*
  • Clinical Trials by End Point Status
    • Table Figure 18: Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics Clinical Trials, Global, by End Point Status, 2022*
    • Table Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics Clinical Trials, Global, by End Point Status, 2022*
  • Subjects Recruited Over a Period of Time
    • Table Figure 19: Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2017-2021
    • Table Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2017-2021
  • Clinical Trials by Sponsor Type
    • Table Figure 20: Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2022*
    • Table Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2022*
  • Prominent Sponsors
    • Table Figure 21: Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics Clinical Trials, Global, Key Sponsors, 2022*
    • Table Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics Clinical Trials, Global, Key Sponsors, 2022*
    • Top Companies Participating in Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics Clinical Trials
      • Table Figure 22: Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2022*
      • Table Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2022*
  • Prominent Drugs
    • Table Figure 23: Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2022*
    • Table Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2022*
  • Clinical Trial Profile Snapshots
  • Appendix
    • Abbreviations
    • Definitions
    • Research Methodology
      • Table Figure 24: GlobalData Methodology
    • Secondary Research
    • About GlobalData
    • Contact Us
  • Source

$2,500
$5,000
$7,500

Research Assistance

US: 800.298.5699
Int'l: +1.240.747.3093
Live help
Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Other tasks

Cookie Settings